Business Description
Pasithea Therapeutics Corp
NAICS : 541714
SIC : 2834
ISIN : US70261F2020
Total Employee Number:
5Description
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 41.7 | |||||
3-Year Book Growth Rate | -58.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.06 | |||||
9-Day RSI | 36.67 | |||||
14-Day RSI | 35.62 | |||||
3-1 Month Momentum % | -27.54 | |||||
6-1 Month Momentum % | -45.05 | |||||
12-1 Month Momentum % | -29.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 35.41 | |||||
Quick Ratio | 35.41 | |||||
Cash Ratio | 33.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -160.8 | |||||
Shareholder Yield % | -379.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -65.6 | |||||
ROA % | -60.94 | |||||
ROIC % | -293.35 | |||||
3-Year ROIIC % | 213.31 | |||||
ROC (Joel Greenblatt) % | -7997.82 | |||||
ROCE % | -73.16 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.21 | |||||
Price-to-Tangible-Book | 0.22 | |||||
EV-to-EBIT | 1.6 | |||||
EV-to-Forward-EBIT | -0.15 | |||||
EV-to-EBITDA | 1.65 | |||||
EV-to-Forward-EBITDA | -0.15 | |||||
EV-to-FCF | 2.08 | |||||
| Price-to-Net-Current-Asset-Value | 0.22 | |||||
| Price-to-Net-Cash | 0.23 | |||||
Earnings Yield (Greenblatt) % | 62.5 | |||||
FCF Yield % | -111.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KTTA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pasithea Therapeutics Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.628 | ||
| Beta | -0.0356 | ||
| 3-Year Sharpe Ratio | -0.81 | ||
| 3-Year Sortino Ratio | -1.07 | ||
| Volatility % | 100.15 | ||
| 14-Day RSI | 35.62 | ||
| 14-Day ATR ($) | 0.049978 | ||
| 20-Day SMA ($) | 0.514 | ||
| 12-1 Month Momentum % | -29.1 | ||
| 52-Week Range ($) | 0.281 - 2.06 | ||
| Shares Outstanding (Mil) | 33.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pasithea Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pasithea Therapeutics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 115 days | ||
| General meeting for 2026 | 2026-09-03 09:00 | In 45 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 24 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.79 (-0.72%) | ||
| Annual report for 2025 | 2026-03-30 | 0.74 (-1.33%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 0.70 (-1.01%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 17:00 | 0.79 (+3.97%) | ||
| General meeting for 2025 | 2025-09-03 09:00 | 0.90 (+9.60%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.72 (+5.43%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 0.96 (+5.76%) |
Show
Entries
Pasithea Therapeutics Corp Frequently Asked Questions
What is Pasithea Therapeutics Corp(KTTA)'s stock price today?
The current price of KTTA is $0.45. The 52 week high of KTTA is $2.06 and 52 week low is $0.28.
When is next earnings date of Pasithea Therapeutics Corp(KTTA)?
The next earnings date of Pasithea Therapeutics Corp(KTTA) is 2026-08-14 Est..
Does Pasithea Therapeutics Corp(KTTA) pay dividends? If so, how much?
Pasithea Therapeutics Corp(KTTA) does not pay dividend.
Guru Commentaries on NAS:KTTA
No articles.
Press Release
Articles on Pasithea Therapeutics Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers